A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF CP-945,598 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS

Registry ID

EUCTR2008-004088-21

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Pfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK

Start date

2008-09-01

Completion date

2008-09-09

Last update

2026-08-16

Conditions

• NON-ALCOHOLIC STEATOHEPATITIS

Summary

To evaluate the efficacy of 20 mg QD and 5 mg QD of CP-945,598 given for 48 weeks in the treatment of NASH.

Locations

• , , UK

View on source registry